On Thursday, Marathon Petroleum Corp (NYSE:MPC)’s shares dwindled -4.60%, and closed at $97.08, formerly on March 20, Marathon Petroleum Corp(NYSE:MPC), declared that it will host a conference call on Thursday, April 30, at 10 a.m. EDT to provide an update on corporation operations and to talk about 2015 first-quarter financial results, which will be released earlier that day.
MPC participants will be Gary Heminger, president and chief executive officer; Don Templin, executive vice president of Supply, Transportation and Marketing; Tim Griffith, senior vice president and chief financial officer; and Mike Palmer, senior vice president of Supply, Distribution and Planning. The call will be hosted by Geri Ewing, director of investor relations.
Marathon Petroleum Corporation: together with its auxiliaries, engages in refining, marketing, retailing, and transporting petroleum products primarily in the United States. It operates through three segments: Refining & Marketing, Speedway, and Pipeline Transportation. The corporation refines crude oil and other feed stocks at its seven refineries in the Gulf Coast and Midwest regions of the United States; and purchases ethanol and refined products for resale.
Microvision, Inc (NASDAQ:MVIS)’s shares dropped -4.36%, and settled at $3.29, during the last trading session on Thursday, soon after Microvision, Inc.(NASDAQ:MVIS), stated it has received an $8 million license fee payment from its Fortune Global 100 partner.
The up-front license fee is part of a multi-year license contract MicroVision declared earlier this month with its Fortune Global 100 partner for MicroVision PicoP® display technology. The license contract grants the Fortune Global 100 Corporation a non-exclusive license to MicroVision PicoP display technology for use in display modules it manufactures and sells. In addition to the initial upfront license fee, MicroVision would also receive royalties for display modules sold by the Fortune Global 100 Corporation. Further terms of the license contract are confidential for competitive reasons.
MicroVision: engages in the development of PicoP display technology that can be used by its customers to create miniature laser display and imaging engines in the United States. Its PicoP display technology comprises a single-mirror micro-electrical mechanical systems scanner, laser diode light sources, electronics, and optics to create a video or still image from a small form factor device.
At the end of Thursday’s trade, Novavax, Inc (NASDAQ:NVAX)’s shares dipped -4.34%, and closed at $7.94, after Novavax, Inc.(NASDAQ:NVAX), stated the closing of the underwritten public offering priced on Wednesday, March 25, 2015. The corporation issued 27,758,620 shares of its ordinary stock, counting 3,620,689 shares following the underwriters’ option to purchase additional shares. The shares were issued at $7.25 per share resulting in total gross proceeds from this offering of about $201,250,000 before deducting the underwriters discount and offering expenses.
J.P. Morgan and Citigroup acted as joint book-running managers of the offering. Piper Jaffray & Co. and Wedbush PacGrow acted as Co-Lead Managers, Janney Montgomery Scott and Ladenburg Thalmann acted as Co-Managers.
Novavax: a clinical-stage vaccine corporation, focuses on discovering, developing, and commercializing recombinant nanoparticle vaccines and adjuvants. The corporation produces its vaccines using its proprietary recombinant nanoparticle vaccine technology.
Intrexon Corp (NYSE:XON), ended its Thursday’s trading session with -4.25% loss, and closed at $41.44, as Intrexon Corp (NYSE:XON), declared that Intrexon has signed a Cooperative Research and Development Contract (CRADA) with the National Cancer Institute (NCI), part of the National Institutes of Health, for the development of adoptive T cell therapies utilizing the RheoSwitch Therapeutic System® (RTS®) platform for the treatment of solid tumor malignancies. The principal aim of the CRADA is to develop and evaluate improved adoptive cell transfer-based immunotherapies (ACT) using NCI proprietary methods for the identification of autologous peripheral blood lymphocytes (PBL) possessing naturally occurring anti-tumor activity combined with Intrexon’s RTS® gene switch for introducing spatially and temporally controlled interleukin-12 (IL-12) expression.
Intrexon Corporation: a biotechnology corporation, operates in the synthetic biology field in the United States. The corporation, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that comprise of key genetic components. Its technologies comprise UltraVector gene design and fabrication platform, and its associated library of modular DNA components; cell systems informatics; RheoSwitch inducible gene switch; AttSite Recombinases; protein engineering; mAbLogix; and laser-enabled analysis and processing.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
